Which EGFR Inhibitors are available?

This directory covers 4: Tagrisso, Tarceva, Iressa, Tykerb.

EGFR Inhibitors

Also called EGFR TKIs, anti-EGFR therapy

EGFR inhibitors block the epidermal growth factor receptor, a protein that is mutated or overactive in a subset of lung and other cancers. In EGFR-mutated non-small-cell lung cancer these oral drugs can shrink tumours dramatically — but resistance usually develops, which is why later generations such as osimertinib were designed to overcome the specific mutations that cause earlier drugs to fail.

What this class is used for

EGFR-mutated non-small-cell lung cancer; some breast and pancreatic cancers

4 EGFR Inhibitors in this directory

Tagrisso

Osimertinib

A targeted oral therapy for EGFR-mutated non-small-cell lung cancer.

Tarceva

Erlotinib

An oral targeted therapy used to treat non-small cell lung cancer and pancreatic cancer.

Iressa

Gefitinib

An oral targeted therapy used to treat EGFR-mutated non-small cell lung cancer.

Tykerb

Lapatinib

An oral targeted therapy used in combination to treat HER2-positive breast cancer.

Compare EGFR Inhibitors side by side

Tagrisso VS Tarceva Tagrisso VS Iressa Tarceva VS Iressa

Browse other drug classes

ARBs Anti-amyloid Antibodies Antibiotics Antibody-drug Conjugates Anticoagulants Anticonvulsants Antihistamines Antiplatelets Asthma & COPD Inhalers Atypical Antipsychotics BTK Inhibitors Beta Blockers CD20 Antibodies CDK4/6 Inhibitors CGRP Inhibitors COVID-19 Antivirals Checkpoint Inhibitors Cholinesterase Inhibitors Complement Inhibitors DPP-4 Inhibitors Enzyme Replacement Therapy GLP-1 Agonists Gene & Cell Therapies HIV Antiretrovirals Hepatitis C Antivirals IL-1 Inhibitors IL-17 Inhibitors IL-23 Inhibitors IL-5 Inhibitors IL-6 Inhibitors Insulins JAK Inhibitors PARP Inhibitors PCSK9 Inhibitors Proton Pump Inhibitors SGLT2 Inhibitors SSRIs & SNRIs Statins TNF Inhibitors TTR Silencers Tyrosine Kinase Inhibitors

Class descriptions are written by the Priya Life Science editorial team. Individual drug pages combine that summary with live label, approval, manufacturer and shortage data from the U.S. FDA via the openFDA API. This page is general information and is not medical advice — it is not exhaustive, drugs within a class are not automatically interchangeable, and approvals and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions. Always consult the official prescribing information and your clinician or pharmacist. Related: Drug Shortages Tracker · FDA Approvals · All drug comparisons